BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 15726522)

  • 21. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801.
    Sarna L; Swann S; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Byhardt R; Wasserman T; Movsas B
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1378-84. PubMed ID: 18501528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment-related esophagitis.
    Werner-Wasik M
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S60-6. PubMed ID: 16015537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002).
    Nishimura Y; Nakagawa K; Takeda K; Tanaka M; Segawa Y; Tsujino K; Negoro S; Fuwa N; Hida T; Kawahara M; Katakami N; Hirokawa K; Yamamoto N; Fukuoka M; Ariyoshi Y
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):786-92. PubMed ID: 17512126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention.
    Mehta V
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):5-24. PubMed ID: 15963660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
    Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
    Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of amifostine in the treatment of carcinoma of the uterine cervix: an update of RTOG-0116 and review of future directions.
    De Los Santos JF; Small W
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):37-41. PubMed ID: 15726521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].
    Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy.
    Komaki R; Chang JY; Wu X; Allen PK; Milas L; Liao Z; Fossella FV; Travis E; Spitz MR
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S92-8. PubMed ID: 16015542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Administration of the cytoprotectant amifostine.
    Lindemann K
    Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy.
    Rodríguez N; Algara M; Foro P; Lacruz M; Reig A; Membrive I; Lozano J; López JL; Quera J; Fernández-Velilla E; Sanz X
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):810-7. PubMed ID: 18755556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.
    Komaki R; Lee JS; Kaplan B; Allen P; Kelly JF; Liao Z; Stevens CW; Fossella FV; Zinner R; Papadimitrakopoulou V; Khuri F; Glisson B; Pisters K; Kurie J; Herbst R; Milas L; Ro J; Thames HD; Hong WK; Cox JD
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):46-9. PubMed ID: 11917284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.
    Han HS; Han JY; Yu SY; Pyo HR; Kim HY; Cho KH; Lee DH; Kim HT; Lee JS
    Cancer; 2008 Oct; 113(7):1623-31. PubMed ID: 18671241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy.
    Takeda K; Nemoto K; Saito H; Ogawa Y; Takai Y; Yamada S
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):626-9. PubMed ID: 15936536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.
    Choy H; Nabid A; Stea B; Scott C; Roa W; Kleinberg L; Ayoub J; Smith C; Souhami L; Hamburg S; Spanos W; Kreisman H; Boyd AP; Cagnoni PJ; Curran WJ
    J Clin Oncol; 2005 Sep; 23(25):5918-28. PubMed ID: 16135463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of cisplatin analogue nedaplatin, paclitaxel, and thoracic radiotherapy for unresectable stage III non-small cell lung cancer.
    Sekine I; Sumi M; Ito Y; Kato T; Fujisaka Y; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
    Jpn J Clin Oncol; 2007 Mar; 37(3):175-80. PubMed ID: 17452427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer.
    Hirose T; Mizutani Y; Ohmori T; Ishida H; Hosaka T; Ando K; Shirai T; Okuda K; Ohnishi T; Horichi N; Kubota H; Adachi M
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):361-7. PubMed ID: 16331494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12.
    Komaki R; Swann RS; Ettinger DS; Glisson BS; Sandler AB; Movsas B; Suh J; Byhardt RW
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):342-50. PubMed ID: 15890573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.